56 related articles for article (PubMed ID: 8888071)
1. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients.
Piscitelli SC; Wells MJ; Metcalf JA; Baseler M; Stevens R; Davey RT
Pharmacotherapy; 1996; 16(5):754-9. PubMed ID: 8888071
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection.
Piscitelli SC; Forrest A; Vogel S; Chaitt D; Metcalf J; Stevens R; Baseler M; Davey RT; Kovacs JA
Clin Pharmacol Ther; 1998 Nov; 64(5):492-8. PubMed ID: 9834041
[TBL] [Abstract][Full Text] [Related]
3. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Piscitelli SC; Vogel S; Figg WD; Raje S; Forrest A; Metcalf JA; Baseler M; Falloon J
Pharmacotherapy; 1998; 18(6):1212-6. PubMed ID: 9855318
[TBL] [Abstract][Full Text] [Related]
4. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers.
Huhn RD; Yurkow EJ; Kuhn JG; Clarke L; Gunn H; Resta D; Shah R; Myers LA; Seibold JR
Clin Pharmacol Ther; 1995 Jan; 57(1):32-41. PubMed ID: 7828379
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
Gustavson LE; Nadeau RW; Oldfield NF
J Biol Response Mod; 1989 Aug; 8(4):440-9. PubMed ID: 2787839
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.
Fortis C; Soldini L; Ghezzi S; Colombo S; Tambussi G; Vicenzi E; Gianotti N; Nozza S; Veglia F; Murone M; Lazzarin A; Poli G
AIDS Res Hum Retroviruses; 2002 May; 18(7):491-9. PubMed ID: 12015902
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
17. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of recombinant interleukin 2 in humans.
Konrad MW; Hemstreet G; Hersh EM; Mansell PW; Mertelsmann R; Kolitz JE; Bradley EC
Cancer Res; 1990 Apr; 50(7):2009-17. PubMed ID: 2317789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
